<DOC>
	<DOCNO>NCT00464971</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . This trial aim evaluate safety efficacy 17-beta Estradiol treatment atrophic vaginitis .</brief_summary>
	<brief_title>Evaluation Safety Efficacy 17-Beta Estradiol Treatment Atrophic Vaginitis : An Extension Trial</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Atrophic Vaginitis</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Generally healthy Postmenopausal Hysterectomized nonhysterectomized Moderate severe vaginal dryness soreness Successful completion study VAG/PD/009/USA Known , suspect , past history breast cancer Known , suspect , past history hormonedependent tumor Genital bleed unknown etiology Acute thrombophlebitis thromboembolic disorder past history condition , associate previous estrogen use Subjects adverse event final visit , discontinue prematurely , noncompliant VAG/PD/009/USA Exposure investigational new drug ( dispensed VAG/PD/009/USA ) within previous 30 day</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>